secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001867096-25-000054
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris appoints James Brady to board, directors Ricki Fairley and John Schmid depart
--------------------------------------------------------------------------------

- Ricki Fairley resigned effective March 28, 2025; no disagreement with company.
- John Schmid will not stand for reelection at 2025 Annual Meeting; board to reduce to eight members.
- James Brady appointed as Class I director, will chair Audit Committee if reelected.
- Brady brings 30+ years at AstraZeneca, most recently CFO of MedImmune; also serves on Verona Pharma (VRNA) board.
- Brady received initial equity grant of 100,000 RSUs under non-employee director compensation plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000054/0001867096-25-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000054/xers-20250328.htm
  HTML page:      https://secwatch.observer/filing/0001867096-25-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer